Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 Combinations in CLDN18.2-positive Advanced Biliary Tract Cancer
NCT07151872Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QLS-31905 in biliary tract cancer (BTC), sponsored by Qilu Pharmaceutical. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QLS-31905
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07151872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151872.